

ESMO Advanced Course on Advanced Breast Cancer: Filling the Gaps Following Progression on CDK4/6 in Hormone Receptor Positive HER2 Negative ABC

PROGRAMME

**ESMO
ADVANCED COURSE**

**DOHA QATAR
16 NOVEMBER 2024**

Co-Chairs

Salha Bujassoum, Qatar
Nadia Harbeck, Germany

ESMO ADVANCED COURSE PROGRAMME

ADVANCED BREAST CANCER: FILLING THE GAPS FOLLOWING PROGRESSION ON CDK4/6 IN HORMONE RECEPTOR POSITIVE HER2 NEGATIVE ABC

Doha, Qatar
16 November 2024

CO-CHAIRS	Salha Bujassoum, Qatar Nadia Harbeck, Germany	MODERATORS	Aydah Alawadhi, United Arab Emirates Ahmed Alfaraj, Saudi Arabia Abdulwahhab Altourah, Kuwait Abdullah Altwairgi, Saudi Arabia Francois Calaud, Qatar Esam Murshid, Saudi Arabia
SPEAKERS	Rupert Bartsch, Austria Alessandra Gennari, Italy Valentina Guarneri, Italy Joana Mourato Ribeiro, France Frédérique Penault-Llorca, France		

LEARNING OBJECTIVES

- Understanding the function and biology of CDK4/6 in breast cancer
- Information and in-depth discussion on the state of the art and emerging therapeutic strategies integrating CDK4/6 inhibition in breast cancer, both in the early and metastatic setting
- Understanding therapeutic options after progression on CDK4/6 inhibitors
- Presenting biomarker data regarding benefit, mechanisms of resistance to CDK4/6 inhibitors and subsequent combinatorial therapeutic strategies
- Discussing the role of oral SERDS in metastatic HR+ HER2- disease
- Defining the role of endocrine-based approaches vs. chemotherapy in HR+ HER2- MBC
- Discussing clinical cancer cases to integrate the use of endocrine-based strategies in clinical practice

ACCREDITATION

The programme of this event has been accredited with **7 ESMO-MORA category 1 points**. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further information please refer to www.esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4, 6900 Lugano, Switzerland
Email: courses@esmo.org | www.esmo.org



Saturday, 16 November 2024

- 09:00-09:10 **Welcome and introduction**
Salha Bujassoum, QT and Nadia Harbeck, DE
- 09:10-09:45 **Session 1 – Epidemiology of Breast Cancer in the Gulf Region**
Moderators: Abdulwahhab Altourah, KW and Francois Calaud, QT
- 20' Salha Bujassoum, QT
- 15' Discussion
- 09:45-11:10 **Session 2 – CDK4/6 inhibitors in EBC and MBC**
Moderators: Abdulwahhab Altourah, KW and Francois Calaud, QT
- 30' Early breast cancer
Nadia Harbeck, DE
- 30' Metastatic breast cancer
Rupert Bartsch, AT
- 25' Discussion
- 11:10-11:40 Coffee break**
- 11:40-13:40 **Session 3 – What to do after CDK4/6 inhibition in advanced breast cancer**
Moderators: Abdullah Altwairgi, SA and Esam Murshid, SA
- 20' Clinically relevant biomarkers (PI3KCA, ESR1, AKT pathway, liquid biopsy, NGS, gBRCA)
Frédérique Penault-Llorca, FR
- 20' CDK4/6 beyond progression and other endocrine based strategies
Valentina Guarneri, IT
- 20' PI3K inhibitors
Joana Mourato Ribeiro, FR
- 30' Oral SERDs
Rupert Bartsch, AT
- 30' Discussion
- 13:40-14:40 Lunch break**
- 14:40-16:00 **Session 4 – Treatment strategies**
Moderators: Abdullah Altwairgi, SA and Esam Murshid, SA
- 20' Management of endocrine sensitive disease
Alessandra Gennari, IT
- 20' Management of endocrine resistant disease
Nadia Harbeck, DE

20'	The potential future for oral SERDs “ongoing clinical trials for oral SERDs” in early & metastatic setting Rupert Bartsch, AT
20'	Discussion
16:00-16:35	Clinical Practice Session – Side effects management Moderators: Ahmed Alfaraj, SA and Aydah Alawadhi, AE
20'	Management of adverse events of new endocrine-based therapies in metastatic breast cancer: Balancing efficacy and toxicity Alessandra Gennari, IT
15'	Discussion
16:35-17:05	<i>Coffee break</i>
17:05-17:45	Workshop Session
Workshop	Molecular Tumour Board HR+ MBC Moderators: Ahmed Alfaraj, SA and Aydah Alawadhi, AE
	30' Presentation of 3 cases by speaker and discussion 10' Discussion
	1. Case: 1st Endocrine resistant PIK3CA mutation – Alessandra Gennari, IT 2. Case: 2nd line ESR1 mutation – Valentina Guarneri, IT 3. Case: gBRCA mutation – Joana Mourato Ribeiro, FR
17:45-17:55	Synthesis and wrap-up